The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 132 results:
[ Author(Desc)] Title Type Year
Filters: Author is Polyzos, Stergios A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., Kountouras J., Anastasiadis S., Doulberis M., & Katsinelos P. (2018).  Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?. Hepatology. 68(1), 389.
Polyzos, S. A., & Mantzoros C. S. (2021).  Diabetes mellitus: 100 years since the discovery of insulin.. Metabolism. 118, 154737.
Polyzos, S. A., Kountouras J., Zafeiriadou E., Patsiaoura K., Katsiki E., Deretzi G., et al. (2011).  Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.. J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
Polyzos, S. A., & Mantzoros C. S. (2016).  Nonalcoholic fatty future disease.. Metabolism. 65(8), 1007-16.
Polyzos, S. A. (2017).  Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease.. Minerva Endocrinol. 42(2), 89-91.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
Polyzos, S. A., Kountouras J., Romiopoulos I., & Polymerou V. (2013).  Serum visfatin in nonalcoholic fatty liver disease.. Ann Hepatol. 13(1), 150-1.
Polyzos, S. A., Slavakis A., Koumerkeridis G., Katsinelos P., & Kountouras J. (2019).  Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.. Horm Metab Res. 51(2), 134-140.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Alterations in serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review.. Thyroid. 20(3), 265-71.
Polyzos, S. A., & Mantzoros C. S. (2023).  Sarcopenia: still in relative definition-penia and severe treatment-penia.. Metabolism. 155717.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2014).  Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease.. Med Hypotheses. 82(6), 795.
Polyzos, S. A., & Kountouras J. (2020).  Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis.. Ann Hepatol. 19(5), 579-580.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2011).  The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistance.. Clinics (Sao Paulo). 66(5), 911-2.
Polyzos, S. A., & Kountouras J. (2015).  Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity.. Helicobacter. 20(6), 405-9.
Polyzos, S. A., Nikolopoulos P., Stogianni A., Romiopoulos I., Katsinelos P., & Kountouras J. (2014).  Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study.. Arq Gastroenterol. 51(3), 261-8.
Polyzos, S. A., & Terpos E. (2016).  Clinical vertebral fractures following denosumab discontinuation.. Endocrine. 54(1), 271-272.
Polyzos, S. A., & Kountouras J. (2019).  CHAI and MACK-3 as noninvasive indices for nonalcoholic steatohepatitis.. Liver Int.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Yavropoulou M. P., & Makras P. (2021).  Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.. Maturitas. 147, 19-25.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2012).  Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease.. J Clin Gastroenterol. 46(4), 272-84.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Makras P., Perakakis N., Kountouras J., et al. (2018).  Irisin in metabolic diseases.. Endocrine. 59(2), 260-274.
Polyzos, S. A., Kountouras J., & Zavos C. (2009).  Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways.. Med Hypotheses. 72(5), 610.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.. Curr Med Chem.
Polyzos, S. A., Kountouras J., Zavos C., Pyrrou N., & Tantsi N. (2013).  Helicobacter pylori infection and serum adiponectin.. Helicobacter. 18(4), 321-2.
Polyzos, S. A., Makras P., Tournis S., & Anastasilakis A. D. (2019).  Off-label uses of denosumab in metabolic bone diseases.. Bone. 129, 115048.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.